133 results on '"Liu, Lianke"'
Search Results
2. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
3. Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
4. Technical scheme of safety monitoring system for urban rail transit operating environment
5. Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
6. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
7. Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer
8. A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors
9. A simple approach towards citrate-stabilized Ag nanoparticles with widely tunable sizes
10. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
11. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101)
12. TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN
13. A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
14. The analysis of CCND1 amplification in Chinese patients with esophageal carcinoma.
15. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
16. Using Next-generation Sequencing as Auxiliary Tool to gastric cancer with multiple intrahepatic neoplasms Diagnosis:primary cholangiocarcinomas or liver metastasis
17. Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review
18. Technical scheme of safety monitoring system for urban rail transit operating environment
19. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
20. Achieving high-purity colloidal gold nanoprisms and their application as biosensing platforms
21. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study
22. Additional file 2 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
23. Additional file 6 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
24. Additional file 8 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
25. Additional file 4 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
26. Additional file 7 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
27. Additional file 5 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
28. Additional file 1 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
29. Additional file 3 of Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
30. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
31. Comprehensive molecular characterization of Chinese patients with intrahepatic and extrahepatic cholangiocarcinoma.
32. Facile purification of colloidal NIR-responsive gold nanorods using ions assisted self-assembly
33. Comparative study of gemcitabine plus cisplatin and gemcitabine plus fluorouracil in the treatment of advanced pancreatic cancer
34. BRAF fusion in lung cancer.
35. The incidence of NTRK fusion in Chinese head and neck cancer and response to crizotinib treatment.
36. Mutational landscape and tumor mutation burden (TMB) feature of biliary cancer.
37. Camrelizumab in the treatment of patients with advanced lung cancer: A multicenter, prospective, cohort study.
38. Utility of circulating tumor DNA in genomic profiling of colorectal cancer with peritoneal metastasis.
39. A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.
40. The Genomic Profiling in Chinese Head and Neck Cancer and Incidence of NTRK Fusion
41. Long-term survival of an unresectable upper thoracic esophageal squamous cell carcinoma with severe dysphagia following nasogastric tube feeding and camrelizumab-containing therapy: a case report
42. Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma
43. MET amplification and exon 14 skipping in treatment naïve patients in lung cancer.
44. A phase I study investigating the absorption, metabolism, and excretion of [14C] anlotinib in patients with advanced refractory solid tumors.
45. Merkel cell carcinoma of the thigh: case report and review of the literature
46. Facile purification of colloidal NIR-responsive gold nanorods using ions assisted self-assembly
47. MiR‐326/Sp1/KLF3: A novel regulatory axis in lung cancer progression
48. A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
49. Oncogenic mutation within the β3-αC loop of EGFR/ERBB2/BRAF/MAP2K1.
50. BRAF V600 and non-V600 mutations across distinct tumor types.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.